Aktiesnakken — Februar 2010
-
indien bliver nok først i 2011
-
jeg har ikke hørt at de har ændret det, ejheller ikke at de har sendt ny analyse, men du kan vente dig den i næste uge efter regnskabet
-
ja bd, det er det jeg har taget udgangspunkt i mine beregninger af konsensuspatienter
-
nej rth men jeg laver en i q1 2011
-
ja den kommer vi uden om
-
men det man kigger på nu, det er nok burn for 2010 og så arzerra forecast
-
best case er burn 400 mill og arzerra 100 mill
-
jeg tror genmab guider mod 1000 patienter i 2010
-
det er stort set det samme, men pricingen er ikke den samme
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind